Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Exclusion criteria

• . Participant has evidence of cardiovascular, pulmonary, central nervous system, hepatic, hematopoietic, renal, or metabolic, endocrine or gastrointestinal disease, or serious allergy, asthma, or allergic skin rash that suggests clinically significant, uncontrolled underlying disease or condition (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.
• . The participant has a co-existing disease affecting the esophagus), (eg, esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus.
• . The participant has a known history of Barrett's with dysplastic changes in the esophagus.
• . The participant has a known history of eosinophilic esophagitis (EoE) or endoscopic findings suggestive of EoE.
• . The participant has a history of celiac disease or the participant tests positive for tTG antibody.
• . The participant has active gastric or duodenal ulcers within 4 weeks prior to Day -1.
• . Participant has any finding in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial.
• . Participant has taken any PPI within 1 week (7 days) prior to the Screening Visit.